M Lion 
Page 1 of 6 
UNIVERSITY OF CALIFORNIA, LOS ANGELES 
CONSENT TO ACT AS A SUBJECT IN A RESEARCH PROJECT 
TITLE: The Treatment of Patients with Metastatic Melanoma and Renal Cell Cancer Using In 
Vitro Expanded and Genetically-Engineered (Neomycin phosphotransferase) Bulk, CD8(+) 
and/or CD4(+) Tumor Infiltrating Lymphocytes and or Bulk, CD8(+) and/or CD4( + ) 
Peripheral Blood Leukocytes in Combination with Recombinant Interleukin-2 alone or with 
Recombinant Interleukin-2 and Recombinant Alpha Interferon. 
INVESTIGATORS: James S. Economou, M.D.,Ph.D., Arie Belldegrun, M.D. Co- 
investigaators: Robert A. Figlin, M.D., E. Carmack Holmes, M.D., Edwin Jacobs, M.D., 
Donald Kohn, M.D., Sidney Golub, Ph.D., Hungyi Shau, Ph.D., William H. McBride, 
Ph.D.,Sc.D., Jean de Kemion, M.D., Robert C. Moen, M.D.,Ph.D. 
PATIENT T ITLE: ADMINISTRATION OF TIL AND PBL 
ADMINISTRATION OF IL-2 AND IFNaA FOR RENAL CELL 
CARCINOMA 
la* 
3 & 
l. 
Patient’s Name UCLA ID Number 
You have the right to know about the procedures that are to be used in your participation in 
clinical research so as to afford you an opportunity to make the decision whether or not to 
undergo the procedure after knowing the risks and hazards involved. This disclosure is not 
meant to frighten or alarm you; it is simply an effort to make you better informed so you may 
give or withhold your consent to participate in clinical research. This informed consent does not 
supersede other informed consents you may have signed. 
Description of Research 
2. Purpose of study : {[ understand that this is an experimental treatment study to treat your 
kidney cancer with immune lymphocytes and interleukin-2 and interferonaA. 
HSPC #91-10-442 
Date of expiration 
1/4/92) 
[554] 
Recombinant DNA Research, Volume 15 
